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Abstract
The recent flood of information about new gene variants associated with chronic disease risk from
genome-wide association studies has understandably led to enthusiasm that genetic discoveries
could reduce disease burdens and increase the availability of direct-to-consumer tests offering risk
information. However, we suggest caution: if it is to be any benefit to health, genetic risk
information needs to prompt individuals to pursue risk-reduction behaviors, yet early evidence
suggests that genetic risk may not be an effective motivator of behavior change. It is not clear how
genetic information will inform risk-based behavioral intervention, or what harms might occur.
Research is needed that examines the behavioral consequences of genetic risk knowledge in the
context of other motivators and social conditions, as well as research that determines the
subgroups of people most likely to be motivated, in order to inform policy decisions about
emerging genetic susceptibility tests. Without such research, it will not be possible to determine
the appropriate health care uses for such tests, the impact on health care resources from
consumer-initiated testing, or the criteria for truthful advertising of direct-to-consumer tests. 
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For families with rare, highly penetrant genetic conditions,
genome medicine is already a reality, with genetic tests that
can identify the family members at high risk of disease. The
rationale for testing is clear: it saves lives in families with
conditions such as multiple endocrine neoplasia type 2,
hereditary breast ovarian cancer syndrome and familial
hypercholesterolemia by directing the use of prophylactic
surgery, intensive screening strategies and specific treat-
ment regimens. With these successes in mind, many people
reasonably hope that similar benefits can be achieved on a
population level by screening for more common genetic
variants associated with disease risk. 
The rapidly expanding number of known risk variants
following from the dramatic success of genome-wide asso-
ciation studies [1] has fueled this vision of ‘personalized
medicine’. The logic is that identification of even modestly
increased risks for common diseases enables providers to
make personalized recommendations for screening and risk
reduction. This assumes that genetic risk information will
motivate behavior, because the greatest gains in prevention
for common complex diseases will come from lifestyle
improvements, such as smoking cessation for heart disease
and lung cancer risk reduction, diet and exercise changes for
diabetes and cancer risk reduction, and adherence to recom-
mended screening guidelines. 
But this vision of individualized genome medicine must be
approached with caution. Most variants emerging from
gene-disease association studies have very small effect sizes,
often with odds ratios of 1.5 or less [2,3], confirming that
susceptibility to common chronic disease reflects a complex
interaction between many different genes and the environ-
ment. Despite an increasing number of direct-to-consumer
tests offering information about common disease suscep-
tibilities, risk information of this sort may be most useful as
an adjunct to current risk assessment, refining rather than
replacing other methods of risk stratification [4]. It is also
unclear whether most behavioral interventions can or should
be individualized for people at moderately increased risk of
disease. Aggressive prevention measures, such as prophy-
lactic surgery, would be ethically and socially unacceptable
for people with moderately increased risk, whereas many
behaviors, such as smoking cessation and regular exercise,
reduce risk for many diseases at all levels of risk [5]. 
Of most concern is the fact that we lack evidence that
individualized risk information is an effective motivator of
behavioral change. There are only a few studies on this issue,
and results have been mixed to weak, with the most con-
vincing evidence suggesting a link between genetic feedback
and adherence to cancer screening [6]. Studies examining
the potential of genetic feedback as a motivator of smoking
cessation have shown neither large nor lasting impacts on
behavior [7]. Optimal communication to patients of genomic
risk is also not well understood and is an important area of
study because achieving behavioral outcomes may be
crucially dependent on how risk is conveyed [8].
Yet genetic risk information is likely to motivate some people
in some circumstances for some behaviors; appropriate
policy requires a further understanding of this motivation.
For this we need high-quality data on the behavioral
consequences of genomic risk information, giving critical
attention to identifying settings in which it has the best
potential to improve health outcomes. There are many robust
theories of behavior change from the social and behavioral
sciences that can guide research. An ecological model - one
that includes the contributions of individual, family,
community, institutions and society to behavior - may be the
most comprehensive, because genes are shared by families
and interaction with the media and health care system are
often steps on a journey to genetic testing [9]. Models of
individual decision-making about health behaviors provide
starting points from which to explore individual reactions to
knowledge of genomic risk [6,10,11,12]. 
For genomic prevention, the best results will come when
genomic risk stratification can inform a prevention program
that is specific to a particular risk group. For example,
people at increased risk for melanoma are likely to benefit
from periodic skin examination to identify potential early
melanomas. The use of genetic risk information is likely to
be persuasive for both patients and physicians. As we
identify and evaluate such opportunities, we need to hold
genomic risk information to the test of comparative
effectiveness [13]: for example, is a DNA-based test to
identify increased risk for melanoma better than the
‘simpler’ genomic test of identifying individuals with pale
skin prone to freckling [14], or than other commonly used
methods of risk assessment, such as family history? 
By contrast, when lifestyle measures have universal value,
personalized prevention is likely to have more to do with
social circumstances than with genetic risk: a person living
in a homeless shelter has much less access to conventional
tobacco cessation programs than a hospital employee, and a
person who has a long commute to work may find it difficult
to exercise. In these cases, policy or environmental measures -
free tailored counseling programs or workplace exercise
space - are likely to offer more benefit than genomic risk
information. Indeed, if the genomic era brings an increased
emphasis on prevention, it may underscore the importance
of risk-independent public health messages as a means to
help improve the health of people most in need. 
Genetic risk information seems to be associated with little
distress or anxiety [11], although this also deserves further
study. Nevertheless, it may be reasonable to assume that the
psychological harms of genetic risk information are minimal,
at least for people who seek such information. How
concerned should we be, then, that many direct-to-consumer
genetic risk profiles are now on the market? The cautions
guiding health care uses of genetic testing are not necessarily
the same as those guiding non-medical uses. Health care
providers and funders have a responsibility to use tests with
proven health value - a standard not yet achieved for genetic
risk information intended to motivate healthy behaviors. But
a consumer product needs merely to be safe. 
For example, a manufacturer of exercise equipment does not
need to prove it will improve health outcomes before
marketing it; the equipment need only comply with
manufacturing standards, and the onus of using it for health
improvement is on the consumer. By similar reasoning, in
the absence of known potential harm, consumer access to
risk information that might, or might not, motivate healthy
behavior can be justified. Yet even here, caution is in order.
Consumers may understandably bring genetic test results to
their physician, potentially generating a cascade of tests and
procedures that would place inappropriate demands on an
already burdened health care system [15,16]. 
We currently lack the knowledge to define when or how
genetic risk information might motivate healthy behavior.
Lacking that knowledge, we are unable to define appropriate
health care uses, impacts on health care resources of
consumer tests or parameters for truthful advertising of
direct-to-consumer tests. Identifying the settings in which
genomic risk can motivate healthy behavior, and perhaps the
individuals most likely to respond to such information, is an
important policy concern. 
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